NASDAQ:BIIB

Biogen News Headlines

$366.87
-7.53 (-2.01 %)
(As of 06/23/2021 11:16 AM ET)
Add
Compare
Today's Range
$365.13
$378.10
50-Day Range
$259.00
$414.71
52-Week Range
$223.25
$468.55
Volume28,725 shs
Average Volume1.58 million shs
Market Capitalization$55.23 billion
P/E Ratio19.25
Dividend YieldN/A
Beta0.44

Biogen (NASDAQ BIIB) News Headlines Today

SourceHeadline
Biogen (NASDAQ:BIIB) Upgraded at Piper SandlerBiogen (NASDAQ:BIIB) Upgraded at Piper Sandler
marketbeat.com - June 18 at 7:32 AM
Biogen Blasts Ahead on Its Alzheimers Drug NewsBiogen Blasts Ahead on Its Alzheimer's Drug News
marketbeat.com - June 8 at 12:06 PM
Biogen (NASDAQ:BIIB) Raised to Outperform at William BlairBiogen (NASDAQ:BIIB) Raised to Outperform at William Blair
marketbeat.com - June 8 at 11:12 AM
3 Healthcare Stocks On The Move After Raising Guidance (BIIB)3 Healthcare Stocks On The Move After Raising Guidance (BIIB)
marketbeat.com - April 22 at 2:56 PM
3 Healthcare Stocks On The Move After Raising Guidance3 Healthcare Stocks On The Move After Raising Guidance
marketbeat.com - April 22 at 2:56 PM
FDA Approved Biogen Alzheimer’s Drug Despite Some Staff ConcernsFDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns
finance.yahoo.com - June 23 at 1:06 AM
FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns - The Wall Street JournalFDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns - The Wall Street Journal
wsj.com - June 22 at 8:03 PM
What in the heck is the FDA thinking?What in the heck is the FDA thinking?
finance.yahoo.com - June 22 at 10:02 AM
Why Cassava Sciences Stock Soared TodayWhy Cassava Sciences Stock Soared Today
finance.yahoo.com - June 21 at 6:06 PM
Why Biogen Isnt a Buy After Its Alzheimers Drug Approval - The Motley FoolWhy Biogen Isn't a Buy After Its Alzheimer's Drug Approval - The Motley Fool
fool.com - June 20 at 7:44 PM
3 More Reasons Biogens Alzheimers Drug Will Underperform Wall Street Expectations - Motley Fool3 More Reasons Biogen's Alzheimer's Drug Will Underperform Wall Street Expectations - Motley Fool
fool.com - June 20 at 2:44 PM
Biogens Alzheimers Drug Deals With CVS and Cigna: What Investors Should Know - The Motley FoolBiogen's Alzheimer's Drug Deals With CVS and Cigna: What Investors Should Know - The Motley Fool
fool.com - June 19 at 11:25 PM
2 Stocks That Could Be Winners in Alzheimers Disease Along With Biogen - The Motley Fool2 Stocks That Could Be Winners in Alzheimer's Disease Along With Biogen - The Motley Fool
fool.com - June 19 at 6:24 PM
2 Stocks That Could Be Winners in Alzheimers Disease Along With Biogen - Nasdaq2 Stocks That Could Be Winners in Alzheimer's Disease Along With Biogen - Nasdaq
nasdaq.com - June 19 at 1:24 PM
Heres Why Sage Therapeutics Tanked This WeekHere's Why Sage Therapeutics Tanked This Week
finance.yahoo.com - June 19 at 8:23 AM
Biogen: 5 Key Questions (And Answers) For Investors Following Aduhelm Approval - Seeking AlphaBiogen: 5 Key Questions (And Answers) For Investors Following Aduhelm Approval - Seeking Alpha
seekingalpha.com - June 19 at 12:30 AM
Biogen Stock Can Go Decisively Higher on Sales of Alzheimers Drug - BarronsBiogen Stock Can Go 'Decisively Higher' on Sales of Alzheimer's Drug - Barron's
barrons.com - June 18 at 2:29 PM
Biogen Commences Dosing In Late-Stage Systemic Lupus Erythematosus Study With BIIB059 - Yahoo FinanceBiogen Commences Dosing In Late-Stage Systemic Lupus Erythematosus Study With BIIB059 - Yahoo Finance
finance.yahoo.com - June 18 at 9:29 AM
Analysis: Rival treatments may help justify FDA gamble with Biogen Alzheimers drug - ReutersAnalysis: Rival treatments may help justify FDA gamble with Biogen Alzheimer's drug - Reuters
reuters.com - June 18 at 9:29 AM
Biogen Stock Can Go 
‘Decisively Higher’ on Sales of Alzheimer’s DrugBiogen Stock Can Go ‘Decisively Higher’ on Sales of Alzheimer’s Drug
finance.yahoo.com - June 18 at 9:28 AM
Dow Jones Today, Futures Tumble As Oil Stocks Dive; Adobe Leaps On Earnings; Biogen UpgradedDow Jones Today, Futures Tumble As Oil Stocks Dive; Adobe Leaps On Earnings; Biogen Upgraded
finance.yahoo.com - June 18 at 9:28 AM
Is It Too Late to Buy Biogen Stock?Is It Too Late to Buy Biogen Stock?
finance.yahoo.com - June 18 at 9:28 AM
Biogen (NASDAQ:BIIB) Rating Increased to Overweight at Piper SandlerBiogen (NASDAQ:BIIB) Rating Increased to Overweight at Piper Sandler
americanbankingnews.com - June 18 at 9:04 AM
Biogen starts dosing in late-stage systemic lupus erythematosus study - Seeking AlphaBiogen starts dosing in late-stage systemic lupus erythematosus study - Seeking Alpha
seekingalpha.com - June 17 at 11:44 PM
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study - Yahoo FinanceBiogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study - Yahoo Finance
finance.yahoo.com - June 17 at 6:44 PM
Biogen halts development of antibody drug aimed at Alzheimers - MarketWatchBiogen halts development of antibody drug aimed at Alzheimer's - MarketWatch
marketwatch.com - June 17 at 6:44 PM
Biogen (BIIB) Ends Development of Anti-Tau Alzheimers DrugBiogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug
finance.yahoo.com - June 17 at 1:37 PM
Biogen Commences Dosing In Late-Stage Systemic Lupus Erythematosus Study With BIIB059Biogen Commences Dosing In Late-Stage Systemic Lupus Erythematosus Study With BIIB059
finance.yahoo.com - June 17 at 1:37 PM
Column: The FDAs hasty approval of a new Alzheimers drug is looking worse than everColumn: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever
finance.yahoo.com - June 17 at 1:37 PM
Following Its Major Regulatory Win, How Much Upside Does Biogen Have? - The Motley FoolFollowing Its Major Regulatory Win, How Much Upside Does Biogen Have? - The Motley Fool
fool.com - June 17 at 8:37 AM
How Has Biogen Soared 61% This Year, But Still Costs Only $1? - Motley FoolHow Has Biogen Soared 61% This Year, But Still Costs Only $1? - Motley Fool
fool.com - June 17 at 8:37 AM
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study - GlobeNewswireBiogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study - GlobeNewswire
globenewswire.com - June 17 at 8:37 AM
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus StudyBiogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
finance.yahoo.com - June 17 at 8:37 AM
Biogen Announces Topline Results From Phase 2 Study of - GlobeNewswireBiogen Announces Topline Results From Phase 2 Study of - GlobeNewswire
globenewswire.com - June 17 at 3:37 AM
 Analysts Anticipate Biogen Inc. (NASDAQ:BIIB) Will Announce Quarterly Sales of $2.61 Billion Analysts Anticipate Biogen Inc. (NASDAQ:BIIB) Will Announce Quarterly Sales of $2.61 Billion
americanbankingnews.com - June 17 at 3:30 AM
Biogen halts development of antibody drug aimed at Alzheimer’sBiogen halts development of antibody drug aimed at Alzheimer’s
finance.yahoo.com - June 16 at 8:48 PM
Biogen: Alzheimer’s Expert Sees ‘Plenty of Patient Demand’ for AduhelmBiogen: Alzheimer’s Expert Sees ‘Plenty of Patient Demand’ for Aduhelm
finance.yahoo.com - June 16 at 8:48 PM
Patient receives first infusion of Biogens controversial Alzheimers drug - CNBCPatient receives first infusion of Biogen's controversial Alzheimer's drug - CNBC
cnbc.com - June 16 at 3:48 PM
Biogens FDA Win Marks a Mini-Rally in Biotech Stocks - BarronsBiogen's FDA Win Marks a Mini-Rally in Biotech Stocks - Barron's
barrons.com - June 16 at 10:48 AM
Biogen Alzheimer’s drug approval was surprising for a lot of people: Eli Lilly CEO - Yahoo FinanceBiogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO - Yahoo Finance
finance.yahoo.com - June 16 at 10:48 AM
Biogen’s FDA Win Marks a Mini-Rally in Biotech StocksBiogen’s FDA Win Marks a Mini-Rally in Biotech Stocks
finance.yahoo.com - June 16 at 10:48 AM
Biogen Alzheimer’s drug approval was surprising for a lot of people: Eli Lilly CEOBiogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO
finance.yahoo.com - June 16 at 10:48 AM
Where Will Biogen Be in 1 Year? - The Motley FoolWhere Will Biogen Be in 1 Year? - The Motley Fool
fool.com - June 15 at 10:56 PM
Biogen says experimental drug for rare retinal disease fails in late-stage clinical trial - MarketWatchBiogen says experimental drug for rare retinal disease fails in late-stage clinical trial - MarketWatch
marketwatch.com - June 15 at 5:55 PM
Biotechs Decline After Sage-Biogen Depression Drug Misses Mark - Yahoo FinanceBiotechs Decline After Sage-Biogen Depression Drug Misses Mark - Yahoo Finance
finance.yahoo.com - June 15 at 5:55 PM
$4.62 Earnings Per Share Expected for Biogen Inc. (NASDAQ:BIIB) This Quarter$4.62 Earnings Per Share Expected for Biogen Inc. (NASDAQ:BIIB) This Quarter
americanbankingnews.com - June 15 at 3:19 PM
Biogen (NASDAQ:BIIB) Stock Rating Reaffirmed by Bank of AmericaBiogen (NASDAQ:BIIB) Stock Rating Reaffirmed by Bank of America
americanbankingnews.com - June 15 at 12:58 PM
Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug - BenzingaBiogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug - Benzinga
benzinga.com - June 15 at 12:55 PM
Biotech Stocks (NBI) Fall After Sage-Biogen (BIIB) Depression Drug Misses Mark - BloombergBiotech Stocks (NBI) Fall After Sage-Biogen (BIIB) Depression Drug Misses Mark - Bloomberg
bloomberg.com - June 15 at 12:55 PM
Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study GoalBiogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal
finance.yahoo.com - June 15 at 12:55 PM
Biotechs Decline After Sage-Biogen Depression Drug Misses MarkBiotechs Decline After Sage-Biogen Depression Drug Misses Mark
finance.yahoo.com - June 15 at 12:55 PM
Sage, Biogen MDD treatment meets primary endpoint - MarketWatchSage, Biogen MDD treatment meets primary endpoint - MarketWatch
marketwatch.com - June 15 at 7:54 AM
Biogen Announces Topline Results from Phase 3 Gene Therapy - GlobeNewswireBiogen Announces Topline Results from Phase 3 Gene Therapy - GlobeNewswire
globenewswire.com - June 15 at 7:54 AM
Biogen Falls Premarket As Eye Disease Treatment Fails TestBiogen Falls Premarket As Eye Disease Treatment Fails Test
finance.yahoo.com - June 15 at 7:54 AM
Sage Therapeutics Plunges After Depression Drug-Trial ResultsSage Therapeutics Plunges After Depression Drug-Trial Results
finance.yahoo.com - June 15 at 7:54 AM
This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.